Literature DB >> 24670186

Thrombotic microangiopathy associated with interferon beta.

David Hunt1, David Kavanagh, Iain Drummond, Belinda Weller, Chris Bellamy, James Overell, Stephen Evans, Andrew Jackson, Siddharthan Chandran.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24670186      PMCID： PMC4066182          DOI： 10.1056/NEJMc1316118

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  2 in total

1.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

2.  Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results.

Authors:  G Giovannoni; O Barbarash; F Casset-Semanaz; J King; L Metz; G Pardo; J Simsarian; P S Sørensen; B Stubinski
Journal:  Mult Scler       Date:  2008-08-28       Impact factor: 6.312
  2 in total
  32 in total

1.  [Current immunotherapy of multiple sclerosis].

Authors:  F Paul; K Ruprecht
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 2.  Drug-induced glomerular disease: attention required!

Authors:  Jai Radhakrishnan; Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-15       Impact factor: 8.237

3.  Active Surveillance of Follow-on Biologics: A Prescription for Uptake.

Authors:  Ameet Sarpatwari; Joshua J Gagne; Nicole L Levidow; Aaron S Kesselheim
Journal:  Drug Saf       Date:  2017-02       Impact factor: 5.606

4.  Thrombotic microangiopathy caused by interferon β-1b for multiple sclerosis: a case report.

Authors:  Haruomi Nishio; Tatsuo Tsukamoto; Takeshi Matsubara; Yoichiro Okada; Ryosuke Takahashi; Motoko Yanagita
Journal:  CEN Case Rep       Date:  2016-06-20

Review 5.  Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature.

Authors:  Lorenzo Gaetani; Paola S Menduno; Francesco Cometa; Maria Di Gregorio; Paola Sarchielli; Carlo Cagini; Paolo Calabresi; Massimiliano Di Filippo
Journal:  J Neurol       Date:  2015-08-21       Impact factor: 4.849

Review 6.  Some recent advances in multiple sclerosis.

Authors:  Claire McCarthy; John Thorpe
Journal:  J Neurol       Date:  2016-04-25       Impact factor: 4.849

Review 7.  [Monitoring of blood parameters under course-modified MS therapy : Substance-specific relevance and current recommendations for action].

Authors:  L Klotz; A Berthele; W Brück; A Chan; P Flachenecker; R Gold; A Haghikia; K Hellwig; B Hemmer; R Hohlfeld; T Korn; T Kümpfel; M Lang; V Limmroth; R A Linker; U Meier; S G Meuth; F Paul; A Salmen; M Stangel; B Tackenberg; H Tumani; C Warnke; M S Weber; T Ziemssen; F Zipp; H Wiendl
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

Review 8.  Drug-induced glomerular disease: direct cellular injury.

Authors:  Glen S Markowitz; Andrew S Bomback; Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-10       Impact factor: 8.237

9.  ERβ-selective agonist alleviates inflammation in a multiple sclerosis model via regulation of MHC II in microglia.

Authors:  Xi Liu; Jing Deng; Rong Li; Changhong Tan; Hongli Li; Zhong Yang; Lifen Chen; Yangmei Chen; Xinjie Tan
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 10.  Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis.

Authors:  Babak Soleimani; Katy Murray; David Hunt
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.